Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

BACKGROUND: Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label phase I/II trial of cabazitaxel plus abiraterone to assess the antitumor activity and tolerability in patients with progressive mCRPC after do...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Oncol
Asıl Yazarlar: Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C. J., Petrylak, D. P., Attard, G., Shen, L., Fizazi, K., de Bono, J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5378222/
https://ncbi.nlm.nih.gov/pubmed/28039155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw441
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller